Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Medicare reimbursement and prescribing hormone therapy for prostate cancer.

Keating NL.

J Natl Cancer Inst. 2010 Dec 15;102(24):1814-5. doi: 10.1093/jnci/djq467. Epub 2010 Dec 3. No abstract available.

PMID:
21131579
2.

Reduction in physician reimbursement and use of hormone therapy in prostate cancer.

Elliott SP, Jarosek SL, Wilt TJ, Virnig BA.

J Natl Cancer Inst. 2010 Dec 15;102(24):1826-34. doi: 10.1093/jnci/djq417. Epub 2010 Dec 3.

3.

Timing of androgen deprivation therapy: some questions answered, others not.

Schellhammer PF.

J Natl Cancer Inst. 2006 Jun 21;98(12):802-3. No abstract available.

PMID:
16788149
4.
5.

[Total androgen blockade].

Namiki M, Mizokami A.

Nihon Rinsho. 2002 Dec;60 Suppl 11:193-8. Review. Japanese. No abstract available.

PMID:
12599570
6.

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.

Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review.

7.

Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer.

Hillner BE, Roberts JD.

J Natl Cancer Inst. 2000 Nov 1;92(21):1704-6. No abstract available.

PMID:
11058606
8.

[Management of a hormone dependent cancer with endocrine therapy--prostate cancer].

Tsukamoto S, Akaza H.

Gan To Kagaku Ryoho. 2001 Jul;28(7):917-26. Review. Japanese.

PMID:
11478140
9.

Reimbursement policy and androgen-deprivation therapy for prostate cancer.

Shahinian VB, Kuo YF, Gilbert SM.

N Engl J Med. 2010 Nov 4;363(19):1822-32. doi: 10.1056/NEJMsa0910784.

10.
11.

[Evolution of endocrine therapy for prostate cancer].

Igawa T, Saito Y.

Nihon Rinsho. 2000 Jul;58 Suppl:176-81. Review. Japanese. No abstract available.

PMID:
11022709
12.

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.

Bayoumi AM, Brown AD, Garber AM.

J Natl Cancer Inst. 2000 Nov 1;92(21):1731-9.

PMID:
11058616
13.

Hormone therapy in advanced prostate cancer.

Forster TH, Stoffel F, Gasser TC.

Front Radiat Ther Oncol. 2002;36:49-65. Review. No abstract available.

PMID:
11842755
14.

Use of combined androgen blockade for advanced prostate cancer in British Columbia.

Chau A, de Lemos ML, Pickles T, Blood P, Kovacic L, Abadi S, Barnett J.

J Oncol Pharm Pract. 2010 Jun;16(2):121-6. doi: 10.1177/1078155209337661. Epub 2009 Jun 18.

PMID:
19541764
15.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

16.

[Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].

Boccon-Gibod L.

Prog Urol. 1997 Feb;7(1):97-8. Review. French. No abstract available.

PMID:
9116748
17.

[Endocrine therapy for prostate cancer in the future].

Usami M.

Gan To Kagaku Ryoho. 1998 May;25(6):817-22. Review. Japanese.

PMID:
9617319
18.

Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis.

Chang SL, Liao JC, Shinghal R.

J Urol. 2009 Jul;182(1):255-60; discussion 261. doi: 10.1016/j.juro.2009.02.141. Epub 2009 May 17.

PMID:
19450844
19.

Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.

Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.

BJU Int. 2008 May;101(9):1096-100. doi: 10.1111/j.1464-410X.2007.07374.x. Epub 2008 Jan 8.

20.

[Significance of neoadjuvant therapy for prostate cancer].

Okada K, Hachiya T.

Nihon Hinyokika Gakkai Zasshi. 1997 Sep;88(9):769-77. Review. Japanese. No abstract available.

Supplemental Content

Support Center